News
Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression
Jan 8, 2020—Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression. View the webcast from TC See the presentation from the Meeting. In the trial, Falkieri met the primary endpoint with statistically significant reductions in MADRS total scoreRead more »
Celon Pharma at J.P. Morgan Annual Healthcare Conference DIGITAL 11-14 January 2021 .
This year, company taking meetings via the Bio Partnering platform during the week of the JP Morgan Healthcare Conference, but will also take part in meetings with foreign investors. Maciej Wieczorek, CEO of Celon Pharma: We have an intensive week of meetings and presentations ahead of us. This year, we use our presence at JPRead more »
Celon Pharma at Jefferies Virtual London Healthcare Conference
The Company’s representatives will take part in the largest pharmaceutical conference in Europe. Maciej Wieczorek, CEO of Celon Pharma S.A.: We are increasing the presence of our products abroad, building a strong position in the segment of inhalation products on the global pharmaceutical market; we are observing that companies from around the world are takingRead more »
The power of science, passion and innovation – video material and on line meeting
Video about R&D Centre with transcript.
The experts agree. The targeted drug against COVID currently developed by Celon Pharma might change the course of the disease.
Thanks to its cutting-edge, innovative approach, Celon Pharma fast-tracks confirmation of the efficacy of its treatment against SARS-COV-2. The new therapeutic approach designed by scientists at Celon Pharma combines the previously dispersed possible responses to the threat brought about by SARS-COV-2. That approach assumes shortening of the infection duration in affected patients and significant limitationRead more »
Results of the PI3K delta study developed by Celon Pharma in the prestigious PLOS Magazine
Results of the PI3K delta study developed by Celon Pharma – CPL302-253 – have been published in the prestigious PLOS Magazine Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma presents the results of the development of a preclinical, highly specific and safe PI3KRead more »
Celon Pharma S.A. is the leader of the Forbes TOP25 of Tech-Medical Industry Ranking
Celon Pharma S.A. has become the leader of the ranking prepared by Forbes magazine. It is the largest, and, more importantly, the most mature biopharmaceutical company developing its own drugs – as justified by the authors of the report, who also underline the Company’s broadest and most advanced portfolio of innovative drugs among Polish biotechRead more »
Dr. Maciej Wieczorek among the speakers at the JAK Inhibitors Drug Development Summit 2020
The CEO of Celon Pharma will participate and hold a presentation at a summit devoted to clinical translation and optimisation of JAK inhibitors. It will also involve interdisciplinary discussions and panels aimed at developing effective JAK inhibitor development strategies and turning them into an effective response to unmet clinical needs of patients in various areas.Read more »